CRSP — Crispr Therapeutics AG

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About Crispr Therapeutics AG

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$53.53
Market Cap$4.86B
Float96.0M
Shares Outstanding96.4M
P/E (Forward)23.36
Price/Sales (TTM)1,184.75
vs. Analyst Target+54.7% to analyst PT
Operating Margin (TTM)-8933.33%
Revenue (TTM)$4.1M
Dividend RateNone
Analyst Target Price$82.82 (28 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $719,000 -$349M -$269M -$345M
2021 $913M $378M $913M $391M
2022 $436,000 -$650M -$110M -$649M
2023 $370M -$154M $240M -$203M
2024 $35.0M -$366M -$75.3M -$447M
2025 $3.5M -$582M -$229M -$549M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $892,000 -$209M
Sep 2025 $889,000 -$106M
Dec 2025 $864,000 -$131M
Mar 2026 $1.5M -$123M

Ownership & Float

Insider Ownership5.9%
Institutional Ownership79.3%
Short Float23.4%
% of All Funds Holding5.51%
Number of Funds Holding453

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$51.20Near-term / short-term trend
Weekly40-Week SMA$55.25Medium-term trend
Weekly80-Week SMA$50.15Cyclical trend (business cycle)
Weekly200-Week SMA$53.68Secular trend (multi-year)
Monthly10-Month SMA$55.01Near-term monthly trend
Monthly20-Month SMA$49.32Medium-term monthly trend
Monthly40-Month SMA$52.48Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$36.80 support 1.69x 10 months ago
$34.00 support 1.35x 12 months ago

Historical Earnings Reactions (39 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.32% 0.06% 53.85% 5.47% -8.88%
1 Day 1.55% 0.71% 58.97% 13.57% -8.70%
1 Week 1.05% -0.36% 48.72% 27.28% -14.39%
2 Weeks 1.59% -0.61% 48.72% 33.87% -24.20%
1 Month 2.32% -0.66% 47.37% 59.75% -35.93%

Next earnings: July 23, 2026 (56 days away)

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan7.3%60.0%10
Feb9.8%70.0%10
Mar-10.5%20.0%10
Apr0.6%70.0%10
May8.9%55.6%9
Jun12.6%77.8%9
Jul4.0%77.8%9
Aug-1.2%44.4%9
Sep-5.8%22.2%9
Oct-4.5%33.3%9
Nov17.3%70.0%10
Dec-6.5%20.0%10

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.45% 54.0% 450
Tuesday 0.22% 49.1% 497
Wednesday 0.03% 49.1% 493
Thursday -0.08% 47.4% 485
Friday 0.07% 47.9% 486

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 79.3%

Insider Transactions — Smart Summary

Total insider ownership: 5.9%

12-Month Insider Activity Summary

Total Filings23
Net Value-$14.6M
Net Shares Change1,043,899
% of Float1.1%
C-Suite Filings21
Clusters Detected1

Key Insiders

NameTitleNet ValueFilingsActivity
George Simeon +$51.5M 1 1 buy
Kulkarni Samarth Chief Executive Officer -$8.6M 2 N/A
Prasad Raju Chief Financial Officer -$1.2M 3 N/A
Treco Douglas A +$1.1M 1 1 buy
Patel Naimish Chief Medical Officer -$243,631.4 3 1 buy

Transaction Clusters

PeriodFilingsInsidersNet ValueSeniority
2026-03-12 – 2026-03-24 9 4 -$2.8M 9 C-suite

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-01-27 Patel Naimish Chief Medical Officer +$49,703.68 Transaction at $32.96, now +62.4%
2025-07-17 George Simeon +$51.5M Transaction at $52.03, now +2.9%
2025-08-08 Treco Douglas A +$1.1M Transaction at $57.03, now -6.1%
2026-03-24 Prasad Raju Chief Financial Officer -$173,460.24 Transaction at $46.78, now +14.4%
2026-03-17 Prasad Raju Chief Financial Officer -$476,277.94 Transaction at $48.26, now +10.9%
2026-03-17 Patel Naimish Chief Medical Officer -$152,019 Transaction at $48.26, now +10.9%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for Crispr Therapeutics AG (CRSP) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for CRSP on Trend Edge →